GenoMed to Market to Malaysia and Singapore


David W. Moskowitz MD
CEO, GenoMed
Tel. 314.983.9938

ST. LOUIS—February 11, 2009—GenoMed® (OTC Pink Sheets GMED.PK) announced today that its CEO, David Moskowitz MD, will continue to market the company’s Next Generation Disease Management service to the developing world, this time to Asia.

In two weeks, GenoMed’s CEO will meet with public health authorities in Kuala Lumpur, Malaysia and Singapore to discuss preventive molecular medicine. The agenda will include how to reverse diabetic and hypertensive kidney failure, as well as delay the progression of emphysema.

The Malaysian National Health Service is responsible for 15 million citizens. Many have diabetes, and kidney failure is a growing problem.

Although Singapore is much smaller, it recently made a bid to become the world leader in biotechnology, having built “Biopolis,” a biotech city, two years ago, and attracted leading scientists from the West to work in it.

Dr. Moskowitz will be in Malaysia to deliver a speech at a healthcare conference ( In his lecture, he will say that leadership in healthcare may be shifting from the First World to the developing world.

Dr. Moskowitz said, “Ironically, the developing world may profit first from advances in personalized medicine. Less infrastructure—fewer hospitals and dialysis units–actually turns out to be an advantage. There’s less financial resistance to clinical innovation. And the Internet allows us to deliver preventive molecular medicine inexpensively anywhere around the globe.”

Dr. Moskowitz will visit Biopolis in Singapore to discuss possible collaboration. Biopolis is already the sort of “virtual” pharmaceutical company that Dr. Moskowitz has predicted will replace Big Pharma. The recent purchase of Wyeth by Pfizer confirms the fact that Big Pharma is disappearing as an industry. A new business model will be required for drug discovery and development.

About GenoMed

GenoMed published how to prevent 90% of kidney failure in 2002. It is now marketing its Next Generation Disease Management service globally to patients with diabetes or high blood pressure. Please contact GenoMed at or

Safe Harbor Statement

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.’s (the Company’s) finances and treatments. The words or phrases “ought to,” “should,” “could,” “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.